Skip to content

A randomized, double-blind, controlled study of theta burst stimulation (TBS) combined with multidisciplinary intensive rehabilitation therapy to improve the rehabilitation efficiency of patients with Parkinson's disease

A randomized, double-blind, controlled study of theta burst stimulation (TBS) combined with multidisciplinary intensive rehabilitation therapy to improve the rehabilitation efficiency of patients with Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056581
Enrollment
Unknown
Registered
2022-02-08
Start date
2022-04-14
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease (PD)

Interventions

Experimental group :theta burst stimulation +multidisciplinary intensive rehabilitation therapy (TBS+MIRT)
Control group:sham-theta burst stimulation +multidisciplinary intensive rehabilitation therapy ( sham-TBS+MIRT)

Sponsors

Beijing Rehabilitation Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for primary Parkinson's disease; 2. H-y stage 2-4; 3. Aged 45-75 years; 4. Patients who have used drugs for more than 2 weeks without adjustment and have not undergone DBS surgery; 5. Can walk without assistance (including auxiliaries).

Exclusion criteria

Exclusion criteria: 1. Cognitive, motor and speech disorders caused by other neurological disorders; 2. History of epilepsy or other contraindications for transcranial magnetic stimulation; 3. Unwilling or unable to participate in MRI examination (claustrophobia); 4. Severe cognitive impairment or audio-visual impairment, unable to communicate and cooperate with the examination; 5. Serious concomitant diseases such as heart, lung, liver and renal insufficiency; 6. Unable to cooperate to complete the training or inspection; 7. Failure to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Parkinson's Disease Unified Rating Scale(III);

Secondary

MeasureTime frame
Parkinson’s Disease Questionnaire-39;Levodopa equivalent dose;Neuroelectrophysiology;Functional MRI;Brain-derived neurotrophic factor;Neuron-specific enolase;Serum homocysteine;

Countries

China

Contacts

Public ContactJin Zhaohui

Beijing Rehabilitation Hospital Affiliated to Capital Medical University

bestvin2004010201@163.com+86 150 1136 7598

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026